novo semaglutide alzheimer's Associations of with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US - Wang - 2024 Novo Nordisk's oral GLP-1 drug
Description
Anderson: A Pioneer Dedicated to Solving Obesity Issues
Results PH is driven by multifactorial mechanisms, including exaggerated insulin secretion, incretin overproduction (GLP-1, GIP), altered glucose absorption, and autonomic dysfunction
Compare that to semaglutide where muscle loss can reach 35-40% of lost weight
Protein Before Noon: A Practical GLP-1 Strategy The main goal is hitting your daily protein target
Retatrutide research demonstrates targeted engagement of the glucagon pathway, enhanced glycemic regulation, and significant weight reduction across metabolic disease models.
Lindsay Crenshaw and the CMA team
